(Q35752823)

10 August 2017

1 reference

title

Monoclonal antibodies in the treatment of chronic lymphoid leukemias (English)

1 reference

10 August 2017

1 reference

1

Tadeusz Robak

1 reference

10 August 2017

language of work or name

1 reference

1 February 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

45

1 reference

10 August 2017

issue

2

1 reference

10 August 2017

page(s)

205-219

1 reference

Anti-CD20-based therapy of B cell lymphoma: state of the art.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

In vitro studies with bendamustine: enhanced activity in combination with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Levels of expression of CD19 and CD20 in chronic B cell leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

CAMPATH-1 antibodies in stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

In vivo 'Purging' of residual disease in CLL with Campath-1H

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

Chimeric monoclonal anti-CD20 antibody (rituximab)--an effective treatment for a patient with relapsing hairy cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000139666

10.1080/1042819031000139666

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference